NCT03587441View on ClinicalTrials.gov

Intrathecal Neostigmine for Prevention of PDPH

PHASE4CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

August 4, 2018

Primary Completion Date

February 5, 2019

Study Completion Date

February 10, 2019

Conditions
Post-Dural Puncture Headache
Interventions
DRUG

Neostigmine Methylsulfate

20 µg Neostigmine Methylsulfate intrathecal in 0.2 ml of Dextrose 5% solution

DRUG

Dextrose 5% in water

intrathecal

Trial Locations (1)

63514

Fayoum University hospital, El Fayoum Qesm

All Listed Sponsors
lead

Fayoum University Hospital

OTHER

NCT03587441 - Intrathecal Neostigmine for Prevention of PDPH | Biotech Hunter | Biotech Hunter